礼来“减肥神药”效果惊人！糖尿病风险降低94%，体重下降近23%

华尔街见闻08-20

诺和诺德“减肥一哥”地位继续遭受礼来冲击！礼来最新研究结果表明，公司开发的GLP-1/GIP减肥药能够显著降低肥胖症患者患上糖尿病的风险。周二，礼来公布了一项长期研究的初步结果：与安慰剂相比，减肥药替尔泊肽(Tirzepatide)能够将肥胖或超重的成年人发展为2型糖尿病的风险降低94%。替尔泊肽是礼来研发的减肥注射剂Zepbound和糖尿病药物Mounjaro中的活性成分。后期试验中还发现，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2460050001?lang=zh_CN&edition=full","thumbnail":"https://wpimg-wscn.awtmt.com/7b76c97f-24fe-42d8-9a25-a62c865fe99b.jpeg","is_english":false,"pubTime":"2024-08-20 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2460050001","market":"us","top_or_hot":-1,"title":"礼来“减肥神药”效果惊人！糖尿病风险降低94%，体重下降近23%","media":"华尔街见闻","content":"<div>\n<p>诺和诺德“减肥一哥”地位继续遭受礼来冲击！礼来最新研究结果表明，公司开发的GLP-1/GIP减肥药能够显著降低肥胖症患者患上糖尿病的风险。\n周二，礼来公布了一项长期研究的初步结果：与安慰剂相比，减肥药替尔泊肽(Tirzepatide)能够将肥胖或超重的成年人发展为2型糖尿病的风险降低94%。\n替尔泊肽是礼来研发的减肥注射剂Zepbound和糖尿病药物Mounjaro中的活性成分。后期试验中还发现，...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3724923\">网页链接</a>\n\n</div>\n","source":"wallstreetcn_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来“减肥神药”效果惊人！糖尿病风险降低94%，体重下降近23%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来“减肥神药”效果惊人！糖尿病风险降低94%，体重下降近23%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-20 21:39 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/articles/3724923><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>诺和诺德“减肥一哥”地位继续遭受礼来冲击！礼来最新研究结果表明，公司开发的GLP-1/GIP减肥药能够显著降低肥胖症患者患上糖尿病的风险。\n周二，礼来公布了一项长期研究的初步结果：与安慰剂相比，减肥药替尔泊肽(Tirzepatide)能够将肥胖或超重的成年人发展为2型糖尿病的风险降低94%。\n替尔泊肽是礼来研发的减肥注射剂Zepbound和糖尿病药物Mounjaro中的活性成分。后期试验中还发现，...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3724923\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BK4W5L77.USD","symbol_name":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","start_time":0,"source_url":"https://wallstreetcn.com/articles/3724923","article_id":"2460050001","we_media_id":null,"thumbnails":["https://wpimg-wscn.awtmt.com/7b76c97f-24fe-42d8-9a25-a62c865fe99b.jpeg"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3724923","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2460050001","pubTimestamp":1724161186,"sourceInfo":{"source_id":"wallstreetcn_hot_news","name":"华尔街见闻"},"weMediaInfo":null,"summary":"礼来研究表明，替尔泊肽能够显著降低肥胖症患者患上糖尿病的风险。后期试验还发现，接受最高周剂量药物的成年人在176周后平均体重下降了22.9%。","collect":0,"end_time":0,"defaultTopTitle":"wallstreetcn.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0882574055.USD":"富达全球健康医疗A ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LLY":"礼来","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0079474960.USD":"联博美国增长基金A","LU0882574139.USD":"富达环球消费行业基金A ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","BK4581":"高盛持仓","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","BK4588":"碎股","LU0385154629.USD":"贝莱德营养科学基金A2","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","NVO":"诺和诺德","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","BK4585":"ETF&股票定投概念"},"translate_title":"Eli Lilly's \"magic medicine for weight loss\" has amazing effects! 94% lower risk of diabetes and nearly 23% weight loss","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1,"NVO":0.7},"content_text":"诺和诺德“减肥一哥”地位继续遭受礼来冲击！礼来最新研究结果表明，公司开发的GLP-1/GIP减肥药能够显著降低肥胖症患者患上糖尿病的风险。\n周二，礼来公布了一项长期研究的初步结果：与安慰剂相比，减肥药替尔泊肽(Tirzepatide)能够将肥胖或超重的成年人发展为2型糖尿病的风险降低94%。\n替尔泊肽是礼来研发的减肥注射剂Zepbound和糖尿病药物Mounjaro中的活性成分。后期试验中还发现，患者在大约三年的治疗期内体重持续下降。接受最高周剂量药物的成年人在176周后平均体重下降了22.9%，而接受安慰剂的人体重下降了2.1%。\n官方最新数据显示，超过1/3的美国人患有糖尿病前期（即血糖异常但未达到糖尿病诊断标准的状态），超重或肥胖的人患糖尿病前期的风险更高。\n礼来的这项研究是迄今为止对替尔泊肽进行的最长研究，涉及超过1000名成年人，持续了176周，并在随后的17周内停止治疗。\n研究结果还显示，即使在停止治疗后，参与者体重有所回升，糖尿病症状加重，但根据第三阶段的最新结果，发展为糖尿病的风险仍然比安慰剂组低88%。\n“这些数据不仅证实了Tirzepatide在减肥方面的显著效果，更重要的是，它们强化了我们对于长期治疗肥胖和糖尿病前期患者潜在临床益处的认识，”礼来产品开发高级副总裁Jeff Emmick表示。\n“肥胖是一种慢性疾病，使全球近9亿成年人面临2型糖尿病等其他并发症的风险增加，”Emmick博士在一份声明中说，“这些数据加强了长期治疗对患有肥胖和糖尿病前期的人的潜在临床益处。”\n替尔泊肽的作用机制是通过模仿肠道产生的两种激素GLP-1和GIP，这两种激素有助于减少食物摄入和食欲，并可能改善身体对糖和脂肪的分解。\n礼来公司表示，这项研究的安全性数据与之前的研究一致，最常见的副作用为胃肠道反应，包括腹泻、恶心、便秘和呕吐，通常为轻度至中度。\n礼来计划将这些结果提交至同行评审期刊发表，并在即将到来的11月医学会议上进行展示。此前，公司已于2022年公布了该试验72周的减肥结果。\n周二美股开盘，礼来股价涨1.6%。\n\n据华尔街见闻此前文章，有研究分析显示，礼来减肥药效果优于诺和诺德。\n报告显示，与服用诺和诺德Ozempic的患者相比，服用Mounjaro的患者减去至少5%的体重的可能性高出76%，减去至少10%的体重的可能性是其的两倍多，减去至少15%的体重的可能性是其的三倍多。\n得益于减肥药大卖，礼来二季度营收同比增长36%，净利润同比暴增68%，双双超过市场预期。公司预测年内减肥药需求继续上升，上调全年营收和利润指引。风险提示及免责条款\n\n            市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460050001"}